Eesti - eesti - Ravimiamet

panpharma laboratories - ketamiin - süstelahus - 50mg 1ml 10ml 25tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psühhoeptikumid, uinutid ja rahustid - koerad - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.

Eesti - eesti - Ravimiamet

laboratoire chauvin s.a. - oksübuprokaiin - silmatilgad, lahus - 4mg 1ml 0.5ml 20tk

Eesti - eesti - Ravimiamet

ao biopharm - püridoksiin - süstelahus - 50mg 1ml 1ml 10tk

Eesti - eesti - Ravimiamet

pat lubnyfarm - püridoksiin - süstelahus - 50mg 1ml 1ml 10tk

Eesti - eesti - Ravimiamet

brooks laboratories limited - püridoksiin - süstelahus - 50mg 1ml 2ml 5tk

Eesti - eesti - Ravimiamet

kimball electronics, inc. - naloksoon - süstelahus eeltäidetud süstevahendis - 10mg 0.4ml 0.4ml 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastilised ained - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioödeem, pärilik - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.